Key Stats for Eli Lilly Stock
- Price change for Eli Lilly stock in last 1 year: 47%
- $LLY Stock Price as of Jul. 23: $1,186
- 52-Week High: $1,249
- $LLY Stock Price Target: $1,270
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock is in the spotlight today after the company said it will file for approval of its next-generation obesity drug, retatrutide, in Q1 of 2027.
This pushes back an earlier plan to submit as soon as this year. Lilly says it simply needs more time to gather and verify the manufacturing and quality-control data regulators require. The delay comes despite strong news on the science side.
Retatrutide just succeeded in two more late-stage trials, bringing its total to five positive Phase 3 studies. In one trial, adults with obesity and type 2 diabetes lost up to an average of 20.8% of their body weight, or nearly 50 pounds, over 80 weeks.
That’s a notable result since this group typically struggles to lose weight. In a second trial, adults with severe obesity and existing heart disease lost up to 22.6% of their weight, or 55.8 pounds, over the same period.
The drug also meaningfully improved certain heart disease risk factors in that group. Side effects stayed consistent with earlier studies and with other drugs in this class, mainly diarrhea, nausea, and constipation.
Based on this data, Lilly believes it now has what it needs to seek global approval for retatrutide covering obesity, knee osteoarthritis pain, and obstructive sleep apnea.
Analysts at TD Cowen estimate retatrutide could bring in $3.8 billion in sales by 2030.
The drug is nicknamed “triple G” because it targets three hormones, GLP-1, GIP, and glucagon, rather than just one or two like existing treatments such as Zepbound or Novo Nordisk’s Wegovy.
Adding to the backdrop, Novo Nordisk said today it’s seeking a court injunction to immediately block certain Eli Lilly ads for its obesity and diabetes drugs.
Novo argues the ads mislead consumers by comparing high doses of Lilly’s Zepbound and Mounjaro against lower doses of Novo’s products.
Lilly has denied wrongdoing and says it will defend its advertising.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
Today’s news is a mixed bag for Eli Lilly stock.
On one hand, five straight positive late-stage trials for retatrutide reinforce Lilly’s position as a leader in the obesity drug race, a market some analysts expect to exceed $100 billion by the 2030s.
On the other hand, pushing the filing timeline back to 2027 means investors will need to wait longer for this next growth driver to reach the market.
The advertising lawsuit from Novo Nordisk adds another layer of competitive tension. As one analyst noted, it signals Novo is taking a more aggressive stance rather than letting Lilly control the narrative in this fast-growing category.
For Eli Lilly stock, the fundamentals around retatrutide look promising, but the timeline delay and heightened rivalry with Novo are worth watching closely in the months ahead.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
